Skip to main content
Premium Trial:

Request an Annual Quote

Wylie Chenn, Samuel Broder, and Shirley Tilghman

Serologicals has named Wylie Chenn as regional director for the Asia/Pacific region, the company said last week. Chenn was most recently general manager, bioscience division for the Asia/Pacific region for Fisher Scientific. He received a BS in marketing and international business from Brigham Young University and an MBA from the University of Washington.


Samuel Broder has joined the board of directors of Protein Design Labs, the Fremont, Calif.-based company said yesterday. He is the chief medical officer of Celera Genomics and Celera Diagnostics. Prior to that, he was senior vice president for research and development at Ivax, and before that, director of the National Cancer Institute. Broder has a medical degree and a bachelor's degree from the University of Michigan.


Google has appointed Shirley Tilghman, Princeton University's president and professor of molecular biology, to its board of directors. Tilghman was a member of the National Research Council committee that guided the US effort in the Human Genome Project and was a founding member of the National Advisory Council of the Human Genome Project Initiative for the National Institutes of Health. She was the founding director of Princeton's multi-disciplinary Lewis-Sigler Institute for Integrative Genomics and became the university's president in June 2001.

 

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.